Manipulating the quality control pathway in transfected cells: Low temperature allows rescue of secretion-defective fibrinogen mutants

Haematologica

Volumn 93, Issue 2, 2008, Pages 224-231

  Vu, Dung ^a   Di Sanza, Corinne ^a   Neerman Arbez, Marguerite ^a,b,c  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c NONE   (Switzerland)

Author keywords

Afibrinogenemia; Chemical chaperones; Fibrinogen; Fibrinogen related domain; Protein quality control; Secretion

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; BLOOD CLOTTING FACTOR 8; DIMETHYL SULFOXIDE; FIBRINOGEN; PLASMIN; TRIMETHYLAMINE OXIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL ASSAY; CELL STRAIN COS7; CONTROLLED STUDY; DYSFIBRINOGENEMIA; FIBRIN CLOT; GENETIC TRANSFECTION; LOW TEMPERATURE; MISSENSE MUTATION; NONHUMAN; PROTEIN SECRETION; QUALITY CONTROL;

AFIBRINOGENEMIA; ANIMALS; CERCOPITHECUS AETHIOPS; COLD; COS CELLS; FACTOR XIII; FIBRINOGEN; GOLGI APPARATUS; HUMANS; MOLECULAR CHAPERONES; MUTATION, MISSENSE; PLASMIN; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 40849134264     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11868     Document Type: Article

References (44)

1. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999;107:204-6.
2. Doolittle RF. A detailed consideration of a principal domain of vertebrate fibrinogen and its relatives. Protein Sci 1992; 1:1563-77.
3. Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen alpha-chain gene (FGA) causes congenital afibrinogenemia. J Clin Invest 1999;103:215-8.
4. Neerman-Arbez M, de Moerloose P. Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations. Hum Mutat 2007;28:540-53.
5. Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007;5[Suppl 1]:125-31.
6. Duga S, Asselta R, Santagostino E, Zeinali S, Simonic T, Malcovati M, et al. Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood 2000;95:1336-41.
7. Vu D, Bolton-Maggs PH, Parr JR, Morris MA, De Moerloose P, Neerman-Arbez M. Congenital afibrinogenemia: identification and expression of a missense mutation in FGB impairing fibrinogen secretion. Blood 2003;102:4413-5.
8. Monaldini L, Asselta R, Duga S, Peyvandi F, Ghosh K, Malcovati M, et al. Fibrinogen Mumbai: intracellular retention due to a novel G434D mutation in the Bbeta-chain gene. Haematologica 2006;91:628-33.
9. Neerman-Arbez M, Vu D, Abu-Libdeh B, Bouchardy I, Morris MA. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. Blood 2003;101:3492-4.
10. Spena S, Asselta R, Duga S, Malcovati M, Peyvandi F, Mannucci PM, et al. Congenital afibrinogenemia: intracellular retention of fibrinogen due to a novel W437G mutation in the fibrinogen Bbeta-chain gene. Biochim Biophys Acta 2003;1639:87-94.
11. Vu D, Di Sanza C, Caille D, de Moerloose P, Scheib H, Meda P, et al. Quality control of fibrinogen secretion in the molecular pathogenesis of congenital afibrinogenemia. Hum Mol Genet 2005;14:3271-80.
12. Vu D, de Moerloose P, Batorova A, Lazur J, Palumbo L, Neerman-Arbez M. Hypofibrinogenaemia caused by a novel FGG missense mutation (W253C) in the gamma chain globular domain impairing fibrinogen secretion. J Med Genet 2005;42:e57.
13. Duga S, Braidotti P, Asselta R, Maggioni M, Santagostino E, Pellegrini C, et al. Liver histology of an afibrinogenemic patient with the Bbeta-L353R mutation showing no evidence of hepatic endoplasmic reticulum storage disease (ERSD); comparative study in COS-1 cells of the intracellular processing of the Bbeta-L353R fibrinogen vs. the ERSD-associated gamma-G284R mutant. J Thromb Haemost 2005; 3:724-32.
14. Zhang JZ, Redman CM. Role of interchain disulfide bonds on the assembly and secretion of human fibrinogen. J Biol Chem 1994;269:652-8.
15. Zhang JZ, Redman C. Fibrinogen assembly and secretion. Role of intrachain disulfide loops. J Biol Chem 1996;271:30083-8.
16. Welch WJ. Role of quality control pathways in human diseases involving protein misfolding. Semin Cell Dev Biol 2004;15:31-8.
17. Bernier V, Lagace M, Bichet DG, Bouvier M. Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab 2004;15:222-8.
18. Perlmutter DH. Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 2002;52:832-6.
19. Fussenegger M, Mazur X, Bailey JE. pTRIDENT, a novel vector family for tricistronic gene expression in mammalian cells. Biotechnol Bioeng 1998;57:1-10.
20. Farrell DH, Huang S, Davie EW. Processing of the carboxyl 15-amino acid extension in the alpha-chain of fibrinogen. J Biol Chem 1993;268:10351-5.
21. Hartwig R, Danishefsky KJ. Studies on the assembly and secretion of fibrinogen. J Biol Chem 1991;266:6578-85.
22. Farrell DH, Mulvihill ER, Huang SM, Chung DW, Davie EW. Recombinant human fibrinogen and sulfation of the gamma' chain. Biochemistry 1991;30:9414-20.
23. Ohashi T, Uchida K, Uchida S, Sasaki S, Nihei H. Intracellular mislocalization of mutant podocin and correction by chemical chaperones. Histochem Cell Biol 2003;119:257-64.
24. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci USA 2000;97:1796-801.
25. Terasawa F, Hogan KA, Kani S, Hirose M, Eguchi Y, Noda Y, et al. Fibrinogen Otsu I:A gammaAsn319,Asp320 deletion dysfibrinogen identified in an asymptomatic pregnant woman. Thromb Haemost 2003;90:757-8.
26. Koopman J, Haverkate F, Briet E, Lord ST. A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the gamma-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Chem 1991;266: 13456-61.
27. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995;73:151-61.
28. Hogan KA, Lord ST, Okumura N, Terasawa F, Galanakis DK, Scharrer I, et al. A functional assay suggests that heterodimers exist in two C-terminal gamma-chain dysfibrinogens: Matsumoto I and Vlissingen/Frankfurt IV. Thromb Haemost 2000;83:592-7.
29. Terasawa F, Kani S, Hongo M, Okumura N. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I. Thromb Res 2006;118:651-61.
30. Hogan KA, Gorkun OV, Lounes KC, Coates AI, Weisel JW, Hantgan RR, et al. Recombinant fibrinogen Vlissingen/ Frankfurt IV. The deletion of residues 319 and 320 from the gamma chain of fibrinogen alters calcium binding, fibrin polymerization, cross-linking, and platelet aggregation. J Biol Chem 2000;275:17778-85.
31. Gorkun OV, Veklich YI, Weisel JW, Lord ST. The conversion of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen. Blood 1997;89:4407-14.
32. Marder VJ, Shulman NR, Carroll WR. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 1969;244: 2111-9.
33. Takagi T, Doolittle RF. Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: amino-terminal sequences of intermediate and terminal fragments. Biochemistry 1975;14:940-6.
34. Lucas MA, Fretto LJ, McKee PA. The relationship of fibrinogen structure to plasminogen activation and plasmin activity during fibrinolysis. Ann N Y Acad Sci 1983;408:71-91.
35. Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments D. Thromb Res 1977;10:803-12.
36. Yamazumi K, Doolittle RF. The synthetic peptide Gly-Pro-Arg-Pro-amide limits the plasmic digestion of fibrinogen in the same fashion as calcium ion. Protein Sci 1992;1:1719-20.
37. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894-904.
38. Hogan KA, Maeda N, Kluckman KD, Lord ST. Synthesis of a mouse model of the dysfibrinogen Vlissingen/Frankfurt IV. Ann N Y Acad Sci 2001;936:117-21.
39. Hogan KA, Merenbloom BK, Kim HS, Lord ST. Neonatal bleeding and decreased plasma fibrinogen levels in mice modeled after the dysfibrinogen Vlissingen/Frankfurt IV. J Thromb Haemost 2004;2:1484-7.
40. Kani S, Terasawa F, Lord ST, Tozuka M, Ota H, Okumura N, et al. In vitro expression demonstrates impaired secretion of the gammaAsn319, Asp320 deletion variant fibrinogen. Thromb Haemost 2005;94:53-9.
41. Binnie CG, Hettasch JM, Strickland E, Lord ST. Characterization of purified recombinant fibrinogen: partial phosphorylation of fibrinopeptide A. Biochemistry 1993;32:107-13.
42. Huang S, Mulvihill ER, Farrell DH, Chung DW, Davie EW. Biosynthesis of human fibrinogen. Subunit interactions and potential intermediates in the assembly. J Biol Chem 1993; 268:8919-26.
43. Iida H, Ishii E, Nakahara M, Urata M, Wakiyama M, Kurihara M, et al. A case of congenital afibrinogenemia: fibrinogen Hakata, a novel nonsense mutation of the fibrinogen gamma-chain gene. Thromb Haemost 2000;84:49-53.
44. Plate M, Asselta R, Peyvandi F, Tenchini ML, Duga S. Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. Biochim Biophys Acta 2007;1772:781-7.